Welcome to LookChem.com Sign In|Join Free
  • or
3-bromomethyl-5-tert-butylthiophene-2-carboxylic acid methyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1361386-46-0

Post Buying Request

1361386-46-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1361386-46-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1361386-46-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,3,8 and 6 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1361386-46:
(9*1)+(8*3)+(7*6)+(6*1)+(5*3)+(4*8)+(3*6)+(2*4)+(1*6)=160
160 % 10 = 0
So 1361386-46-0 is a valid CAS Registry Number.

1361386-46-0Downstream Products

1361386-46-0Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

-

Paragraph 0505, (2016/05/02)

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

NOVEL TRIAZINE DERIVATIVE

-

, (2015/02/02)

To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I) : wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted he

INHIBITORS OF BRUTON'S TYROSINE KINASE

-

, (2014/05/24)

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with exc

INHIBITORS OF BRUTON'S TYROSINE KINASE

-

, (2014/06/11)

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

-

, (2012/03/26)

Pyridazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

-

, (2012/03/26)

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1361386-46-0